BioCardia Future Growth

Future criteria checks 2/6

BioCardia's earnings are forecast to decline at 13.5% per annum while its annual revenue is expected to grow at 94.1% per year. EPS is expected to grow by 30.3% per annum.

Key information

-13.5%

Earnings growth rate

30.3%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate94.1%
Future return on equityn/a
Analyst coverage

Low

Last updated14 Nov 2024

Recent future growth updates

Recent updates

Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable

May 14
Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable

Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns

Oct 12
Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns

BioCardia stock rises on contract for delivery products for BlueRock's cell therapies

Aug 24

Will BioCardia (NASDAQ:BCDA) Spend Its Cash Wisely?

Aug 24
Will BioCardia (NASDAQ:BCDA) Spend Its Cash Wisely?

Here's Why We're Watching BioCardia's (NASDAQ:BCDA) Cash Burn Situation

May 10
Here's Why We're Watching BioCardia's (NASDAQ:BCDA) Cash Burn Situation

We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully

Jan 06
We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully

We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully

Sep 23
We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully

Earnings and Revenue Growth Forecasts

NasdaqCM:BCDA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20260-13N/AN/A1
12/31/20250-11N/AN/A1
12/31/20240-10N/AN/A1
9/30/20240-8-7-7N/A
6/30/20240-9-7-7N/A
3/31/20240-10-9-9N/A
12/31/20230-12-10-10N/A
9/30/20231-13-11-11N/A
6/30/20230-13-11-11N/A
3/31/20231-12-10-10N/A
12/31/20221-12-11-11N/A
9/30/20221-12-11-11N/A
6/30/20222-12-11-11N/A
3/31/20221-13-12-11N/A
12/31/20211-13-10-10N/A
9/30/20211-12-11-11N/A
6/30/20210-13-12-12N/A
3/31/20210-13-11-11N/A
12/31/20200-15-12-12N/A
9/30/20200-16-12-12N/A
6/30/20200-15-10-10N/A
3/31/20201-16-10-10N/A
12/31/20191-15-10-9N/A
9/30/20191-15-10-9N/A
6/30/20190-15-10-10N/A
3/31/20191-14-11-10N/A
12/31/20181-14-11-11N/A
9/30/20181-14-10-10N/A
6/30/20181-13N/A-10N/A
3/31/20181-13N/A-9N/A
12/31/20170-12N/A-9N/A
9/30/20171-12N/A-9N/A
6/30/20171-13N/A-8N/A
3/31/20171-12N/A-7N/A
12/31/20161-10N/A-6N/A
9/30/20161-7N/A-4N/A
6/30/20161-7N/A-5N/A
3/31/20161-6N/A-6N/A
12/31/20151-7N/A-7N/A
3/31/20151-10N/A-6N/A
12/31/20141-10N/A-6N/A
12/31/20132-6N/A-5N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BCDA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BCDA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BCDA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BCDA's revenue (94.1% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: BCDA's revenue (94.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BCDA's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 12:04
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioCardia, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joseph PantginisH.C. Wainwright & Co.
Emanuela BranchettiH.C. Wainwright & Co.